4-[((2R)-Hydroxy-3-phthalimido)propylamine]phenyl-3-morpholinone
Product Code
TRC-H948920
CAS Number
Product Format
Neat
Molecular Formula
C21 H21 N3 O5
Molecular Weight
395.41
Product Categories
Documentation
Looking for another lot?
To view all certificates of analysis immediately, please login to your account
or
{{ errors.first('lotNumber') }}
{{ errors.first('requestEmail') }}
For information about our data processing activities, please visit our Privacy Notice.
Enter your email address and we'll email you the relevant CoA for lots:
{{ coaPopupData.packSize.coaSelectedLotNumbers }}
{{ errors.first('coaEmail') }}
We will be sending the CoA to your email address {{ coaEmailPopupData.userEmail }}
Your request has been sent to our sales team to process.
Find an SDS for your region
{{ errors.first('selectedRegion') }}
{{ errors.first('sdsEmail') }}
For information about our data processing activities, please visit our Privacy Notice.
Your request has been sent to our sales team to process.
Product Information
Chemical Data
Analyte Name
2-[(2R)-2-Hydroxy-3-[(4-(3-oxo-4-morpholinyl)phenyl)amino]propyl]-1H-isoindole-1,3(2H)-dione
CAS Number
446292-07-5
Molecular Formula
C21 H21 N3 O5
Molecular Weight
395.41
Accurate Mass
395.1481
SMILES
O[C@H](CNc1ccc(cc1)N2CCOCC2=O)CN3C(=O)c4ccccc4C3=O
InChI
InChI=1S/C21H21N3O5/c25-16(12-24-20(27)17-3-1-2-4-18(17)21(24)28)11-22-14-5-7-15(8-6-14)23-9-10-29-13-19(23)26/h1-8,16,22,25H,9-13H2/t16-/m1/s1
IUPAC
2-[(2R)-2-hydroxy-3-[4-(3-oxomorpholin-4-yl)anilino]propyl]isoindole-1,3-dione
Product Data
Storage Temperature
+4°C
Shipping Temperature
Room Temperature
Country of Origin
CANADA
Product Format
Neat
Product Description
4-[((2R)-Hydroxy-3-phthalimido)propylamine]phenyl-3-morpholinone is a Rivaroxaban (R538000(P)) intermediate. Rivaroxaban is a novel antithrombotic agent. It is also a highly potent and selective, direct FXa inhibitor.
References: Roehrig, S., et al.: J. Med. Chem., 48, 5900 (2005), Ansell, J., et al.: Drugs, 64, 1 (2004), Eriksson, B., et al.: J. Thromb. Haemost., 3, 103 (2005), Kubitza, D., et al.: Clin. Pharmacol. Ther., 78, 412 (2005),